NO993654L - Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker - Google Patents

Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker

Info

Publication number
NO993654L
NO993654L NO993654A NO993654A NO993654L NO 993654 L NO993654 L NO 993654L NO 993654 A NO993654 A NO 993654A NO 993654 A NO993654 A NO 993654A NO 993654 L NO993654 L NO 993654L
Authority
NO
Norway
Prior art keywords
benzimidazole
chemotherapeutic agent
enhancer
kit
optionally
Prior art date
Application number
NO993654A
Other languages
English (en)
Other versions
NO993654D0 (no
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO993654D0 publication Critical patent/NO993654D0/no
Publication of NO993654L publication Critical patent/NO993654L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metode for å inhibere vekst av tumorer og cancere i pattedyr som omfatter administrering av et kjemoterapeutisk middel for å signifikant redusere tumormassen og deretter administrering av et benzimidazolderivat. Forsterkere kan også være inklu- dert i benzimidazolmiddelet.
NO993654A 1997-01-28 1999-07-27 Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker NO993654L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/788,482 US5900429A (en) 1997-01-28 1997-01-28 Method for inhibiting the growth of cancers
PCT/US1998/001147 WO1998032440A1 (en) 1997-01-28 1998-01-21 Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator

Publications (2)

Publication Number Publication Date
NO993654D0 NO993654D0 (no) 1999-07-27
NO993654L true NO993654L (no) 1999-09-28

Family

ID=25144634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993654A NO993654L (no) 1997-01-28 1999-07-27 Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker

Country Status (19)

Country Link
US (3) US5900429A (no)
EP (1) EP0967977A1 (no)
JP (1) JP2001509164A (no)
KR (1) KR20000070551A (no)
CN (1) CN1244123A (no)
AR (1) AR011583A1 (no)
AU (1) AU729099B2 (no)
BR (1) BR9807003A (no)
CA (1) CA2277166A1 (no)
CZ (1) CZ265499A3 (no)
HU (1) HUP0001939A3 (no)
ID (1) ID23507A (no)
IL (1) IL131097A0 (no)
NO (1) NO993654L (no)
PL (1) PL335054A1 (no)
SK (1) SK99199A3 (no)
TR (1) TR199901768T2 (no)
WO (1) WO1998032440A1 (no)
ZA (1) ZA98643B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
DE19710907A1 (de) * 1997-03-15 1998-09-17 Pascoe Pharm Praeparate Gmbh Ascorbinsäure als Adjuvans in der Chemo- und Strahlentherapie von Malignomen
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
EP1154819A2 (en) * 1999-02-26 2001-11-21 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
WO2000050021A2 (en) * 1999-02-26 2000-08-31 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
CA2369263A1 (en) * 1999-04-09 2000-10-19 Jessie Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6462062B1 (en) * 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
AU2002248341B8 (en) * 2001-01-11 2007-03-29 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6515074B2 (en) * 2001-01-22 2003-02-04 Delphi Technologies, Inc. Thermoplastic polymer alloy compositions and process for manufacture thereof
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2008108741A1 (en) * 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
CN101816794A (zh) * 2001-06-25 2010-09-01 味之素株式会社 抗肿瘤剂
CN101111248A (zh) * 2004-12-06 2008-01-23 新南部创新有限公司 癌症的治疗
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
JP7313059B2 (ja) 2017-05-08 2023-07-24 メハリー メディカル カレッジ 精子細胞を強化するためのヒドロキシ尿素

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) * 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (no) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) * 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) * 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) * 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) * 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) * 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) * 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) * 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) * 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5364875A (en) * 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5310748A (en) * 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5290801A (en) * 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
JPH08500112A (ja) * 1992-08-12 1996-01-09 ジ・アップジョン・カンパニー タキソールと組み合わせるプロテインキナーゼ阻害剤および関連化合物
RO118000B1 (ro) 1993-03-31 2002-12-30 Merck & Co Inc Metoda pentru tratamentul sida, prevenirea si tratamentul infectiei cu hiv sau inhibarea proteazei hiv si compozitie farmaceutica pentru aplicarea metodei
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) * 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
NZ305784A (en) * 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
BR9604973A (pt) 1995-04-12 1998-06-09 Procter & Gamble Uma composição farmacêutica contendo carbamatos de n-cloro fenila e tiocarbamatos de n-cloro fenila para inibição de crescimento de vírus e cânceres
US5629341A (en) * 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) * 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
AU717382B2 (en) 1995-06-07 2000-03-23 Procter & Gamble Company, The Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
WO1997005870A2 (en) 1995-08-03 1997-02-20 The Procter & Gamble Company Use of griseofulvin for inhibiting the growth of cancers
CA2229024A1 (en) 1995-08-04 1997-02-20 The Procter & Gamble Company Use of fluconazole for inhibiting the growth of cancers
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
ID23507A (id) 2000-04-27
TR199901768T2 (xx) 1999-09-21
KR20000070551A (ko) 2000-11-25
HUP0001939A2 (hu) 2001-01-29
ZA98643B (en) 1998-07-30
WO1998032440A1 (en) 1998-07-30
US6329355B1 (en) 2001-12-11
AU729099B2 (en) 2001-01-25
IL131097A0 (en) 2001-01-28
CA2277166A1 (en) 1998-07-30
EP0967977A1 (en) 2000-01-05
NO993654D0 (no) 1999-07-27
AR011583A1 (es) 2000-08-30
HUP0001939A3 (en) 2002-08-28
PL335054A1 (en) 2000-03-27
JP2001509164A (ja) 2001-07-10
US5900429A (en) 1999-05-04
CN1244123A (zh) 2000-02-09
AU6034398A (en) 1998-08-18
SK99199A3 (en) 2000-05-16
US6271217B1 (en) 2001-08-07
BR9807003A (pt) 2000-03-14
CZ265499A3 (cs) 1999-12-15

Similar Documents

Publication Publication Date Title
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO2004043389A3 (en) Methods of treating cancer and related methods
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
IS5025A (is) Samtengd efnasambönd nytsamleg við meðhöndlunina á krabbameini í blöðruhálskirtli
AU2003273176A1 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
TR200001687T2 (tr) Neopleasyo için N-benzil-3-indenilasetamid türevleri.
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
NO20031531D0 (no) Fremgangsmåter for reduksjon av kreftcelledöd og tumorregresjon
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
DK1044005T3 (da) 1,2,4-Benzotriazinoxidformuleringer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
NO20016380L (no) Fremgangsmåte for å forhindre tumorvekst
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
WO1998007415A3 (en) Methods for prevention of cellular proliferation and restenosis
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
AU2003297639A1 (en) Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
ATE243698T1 (de) 1,2-dihydro-1-oxo-pyrazino(1,2-)indolederivate
NO973871L (no) Benzotiopyranoindazoler som antitumormidler
RO117697B1 (ro) Metodă de chimioterapie fotostimulată, pentru tratamentul tumorilor solide, maligne
AU2003251446A1 (en) Formulation of liposomal derivatives of phenylalanine
CO5170496A1 (es) Metodo para el tratamiento de la familia de tumores de ewina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application